Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals has reported a significant increase in its financials for Q2 2024, with a 38% growth in total net revenue and a 34% rise in net product revenue, alongside a strong cash position of $330.7 million. The company has also narrowed its revenue guidance for 2024 and is advancing its pipeline with the development of AUR200, a promising treatment for autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.